Drug Drug Description; Daclizumab: A monoclonal anti-CD25 antibody that blocks the interleukin-2 receptor which is used to treat relapsing forms of multiple sclerosis. Basiliximab: A monoclonal anti-C25 antibody (interleukin-2 receptor alpha subunit) used as immunosuppressive therapy in kidney transplant patients.
Interleukin-2 (IL-2) Inhibitor Emerging Drugs Chapters This segment of the Interleukin-2 (IL-2) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical
Interleukin-2 (IL-2), Aldesleukin chemotherapyTreatment of cancer patients with anticancer drugs. Commonly called 'chemo'. remissionA period of time in which
To date, there are four drugs approved by the Food and Drug Administration for melanoma (dacarbazine, interleukin-2, ipilimumab and vemurafenib). Despite
New understanding of immune modulator interleukin-2 guides drug discovery The signaling molecule interleukin-2 (IL-2) has long been known to
Interleukin-2 (IL-2) is a cytokine that is critical to the regulation of T-cell responses Drugs eBooks. Life Sciences Links. Life Sciences
Interleukin; Interleukin-1 beta; Interleukin-1b; Interleukin1 beta. View drug positive regulation of T cell proliferation positive regulation of NF
Drug Drug Description; Daclizumab: A monoclonal anti-CD25 antibody that blocks the interleukin-2 receptor which is used to treat relapsing forms of multiple sclerosis. Basiliximab: A monoclonal anti-C25 antibody (interleukin-2 receptor alpha subunit) used as immunosuppressive therapy in kidney transplant patients.
Aldesleukin; Interleukin-2; Capecitabine; Carboplatin. The common feature these drugs have is their tendency to cause weight
Comments